seem to be [10:20% of body surface area. f The risk of adrenal suppression appears to increase with decreasing age. b (See Systemic Effects under Cautions.) Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol concentrations, and lack of response to corticotropin (ACTH) stimulation. b c d e Children also are at greater risk of glucocorticoid insufficiency during and/or after withdrawal of treatment. b c d e Intracranial hypertension has occurred in children; manifestations include bulging fontanelles, headaches, and bilateral papilledema. b c d e Topical corticosteroid therapy in children should be limited to the minimum amount necessary for therapeutic efficacy; chronic topical corticosteroid therapy may interfere with growth and development. b c d e Common Adverse Effects Burning, hypertrichosis, maceration of the skin, itching, acneiform eruptions, secondary infection, irritation, hypopigmentation, periorbital dermatitis, skin atrophy, dryness, folliculitis, striae, allergic contact dermatitis, miliaria. c d e Interactions for Desoximetasone Specific Drugs and Laboratory Tests Drug or Test Interaction Nitroblue-tetrazolium test for bacterial infection Concurrent use of corticosteroids reportedly may result in false-negative results b Desoximetasone Pharmacokinetics Absorption Bioavailability Topically applied desoximetasone can be absorbed through normal intact skin. b c d e Percutaneous penetration of corticosteroids following topical application to the skin varies among individuals and may be increased by occlusive dressings, high corticosteroid concentrations, and certain vehicles. b Only minimal amounts of topical corticosteroid reach the dermis and subsequently the systemic circulation after application to most normal skin areas; more absorption occurs from the scrotum, axilla, eyelid, face, and scalp than from the forearm, knee, elbow, palm, and sole. b Absorption is markedly increased by loss of the skin s keratin layer and by inflammation and/or diseases of the epidermal barrier (e.g., psoriasis, eczema). b Distribution Extent Not known whether topical desoximetasone is distributed into milk. c Elimination Metabolism Once absorbed through the skin, topically applied corticosteroids are metabolized primarily in the liver. b c d e Elimination Route Topical corticosteroids and metabolites are excreted by the kidneys and, to a lesser extent, in bile. b c d e Half-life Topical cream:15 17 hours. c d e Stability Storage Topical Cream, ointment, and gel:15 30 C; well-closed container. a c Actions Precise mechanism of action for topical anti-inflammatory activity is unknown; therapeutic benefit in the management of corticosteroid-responsive dermatoses mediated primarily through anti-inflammatory, antipruritic, and vasoconstrictive actions. c d e Decreases inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation; and possibly by other mechanisms as yet unknown. b Advice to Patients Importance of using only as directed, only for the disorder for which it was prescribed, and for no longer than prescribed; avoid contact with the eyes and only apply externally as directed. c d e (See Topical Administration under Dosage and Administration.) Importance of informing patients that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by a clinician. c d e Importance of reporting any local adverse reactions, especially those occurring under occlusive bandage, to a clinician. b c d e Importance of informing parents of children not to use diapers or plastic pants on children being treated in the diaper area as these garments may act as occlusive dressings. c d e Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs. c d e Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. c d e Importance of advising patients of other important precautionary information. (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. * available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name Desoximetasone Routes Dosage Forms Strengths Brand Names Manufacturer Topical Cream 0.05% Desoximetasone Cream Taro Topicort LP Taro 0.25%* Desoximetasone Cream Perrigo, Taro Topicort Taro Gel 0.05% Desoximetasone Gel (with SD alcohol 40 20%w/w) Perrigo, Taro Topicort (with SD alcohol 40 20% w/w) Taro Ointment 0.25% Topicort (with propylene glycol) Taro Desoximetasone Ointment Fougera, Taro AHFS DI Essentials. Copyright 2017, Selected Revisions January 1, 2008. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References a. AHFS drug information 2007. McEvoy GK, ed. Desoximetasone. Bethesda, MD: American Society of Health-Systems Pharmacists; 2007:3530. b. AHFS drug information 2007 McEvoy GK, ed. Topical corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2005:3423 5. c. Taro Pharmaceuticals. Topicort (desoximetasone) prescribing information. Hawthorne, NY; 2006 May. d. Perrigo, Inc. Desoximetasone gel USP, 0.05% prescribing information. Allegan, MI; 2006 Oct. e. Perrigo. Desoximetasone cream USP, 0.25% prescribing information. Allegan, MI; 2006 Oct. f. Connetics Corporation. Verdeso (desonide) aerosol, foam prescribing information. Palo Alto, CA; 2006 Oct. Next Interactions Print this page Add to My Med List More about desoximetasone topical Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 21 Reviews Add your own review/rating Drug class: topical steroids Consumer resources Desoximetasone topical ... +3 more Professional resources Desoximetasone Cream (FDA) Desoximetasone Gel (FDA) Desoximetasone Ointment (FDA) Desoximetasone (Wolters Kluwer) Other brands: Topicort Related treatment guides Atopic Dermatitis Dermatitis Psoriasis Eczema] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturers Akorn, Inc. Lupin Pharmaceuticals, Inc. Perrigo Company Sandoz Inc. Taro Pharmaceuticals U.S.A., Inc. Teva Pharmaceuticals USA, Inc. Glenmark Pharmaceuticals Inc., USA VersaPharm Incorporated More... Drug Class Topical steroids Related Drugs Eczema prednisone , fluticasone topical , triamcinolone topical , hydrocortisone topical , dexamethasone , clobetasol topical , More... Atopic Dermatitis prednisone , fluticasone topical , triamcinolone topical , hydrocortisone topical , dexamethasone , methylprednisolone , More... Dermatitis fluticasone topical , triamcinolone , hydrocortisone topical , prednisolone , clobetasol topical , More... Psoriasis Humira , methotrexate , cyclosporine , Remicade , adalimumab , infliximab , More... Desoximetasone topical Rating 21 User Reviews 8.7 /10 21 User Reviews 8.7 Rate it! profits
a chronic Desoximetasone training session
EmoticonEmoticon